| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 09/18/2002 | EP1104762B1 Substituted imidazo[1,2a]azines as selective inhibitors of cox-2 |
| 09/18/2002 | EP1036059B1 Adamantane derivatives |
| 09/18/2002 | EP1000034B1 Substituted 6-alkylphenanthridines |
| 09/18/2002 | EP0934259B1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 09/18/2002 | EP0929516B1 Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect |
| 09/18/2002 | EP0904260B1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids |
| 09/18/2002 | CN1370238A Human poly(ADP-ribose) polymerase 2 materials and methods |
| 09/18/2002 | CN1370181A Effectors of dipeptidyl peptidase IV for topical use |
| 09/18/2002 | CN1370163A Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives |
| 09/18/2002 | CN1370161A Novel quaternary ammonium compounds, its prepn. methods and medicinal application |
| 09/18/2002 | CN1370159A Indole derivatives and their use for treatment of osteoporosis amongst other applications |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370152A 5-cyano-2-aminopyrimidine derivatives |
| 09/18/2002 | CN1370147A Novel integrin alpha V\ beta3 inhibitors |
| 09/18/2002 | CN1370146A Alpha/Beta integrin inhibitors |
| 09/18/2002 | CN1370143A Propanoic acid derivatives that inhibit binding of integrins to their receptors |
| 09/18/2002 | CN1370076A HM 1.24 antigen expression potentiators |
| 09/18/2002 | CN1370071A Drug for treating fractures |
| 09/18/2002 | CN1369299A Medicine for treating osteoarthritis and its preparing process and application |
| 09/18/2002 | CN1369298A Capsule for treating hemiplegia and rheumatism |
| 09/18/2002 | CN1369284A Medicinal composition for quickly treating bone fracture |
| 09/18/2002 | CN1369277A Exterior-applied plaster for treating lumbar vertebra disease, cervical vertebra disease and osteoarthropathy and its preparing process |
| 09/18/2002 | CN1090966C Ointment |
| 09/18/2002 | CN1090953C Prepn. and use of external-use medicine for cardiac and cerebral vascular diseases and rhematism |
| 09/18/2002 | CN1090945C Bone setting capsle and its preparing process |
| 09/17/2002 | US6452001 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 09/17/2002 | US6451859 C16 unsaturated FP-selective prostaglandins analogs |
| 09/17/2002 | US6451858 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 09/17/2002 | US6451842 Cyclic amine derivatives and their use as drugs |
| 09/17/2002 | US6451839 Indole sPLA2 inhibitors |
| 09/17/2002 | US6451838 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/17/2002 | US6451834 Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives |
| 09/17/2002 | US6451824 Sulfonylaminocarboxylic acids |
| 09/17/2002 | US6451812 Farnesyl protein transferase inhibitors for treating arthropathies |
| 09/17/2002 | US6451804 Heteroalkylamino-substituted bicyclic nitrogen heterocycles |
| 09/17/2002 | US6451801 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 09/17/2002 | US6451794 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors |
| 09/17/2002 | US6451791 Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| 09/17/2002 | US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8 |
| 09/17/2002 | US6451307 3′-exonuclease, production and use thereof |
| 09/17/2002 | CA2243459C Human antibodies that bind human tnf.alpha. |
| 09/12/2002 | WO2002070742A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | WO2002070741A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | WO2002070737A2 Compositions and methods relating to osteoarthritis |
| 09/12/2002 | WO2002070706A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070657A2 93870, a human g-protein coupled receptor and uses therefor |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070523A1 Modulators of chemokine receptor activity |
| 09/12/2002 | WO2002070517A2 Cathepsin cysteine protease inhibitors |
| 09/12/2002 | WO2002070515A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | WO2002070502A1 Dimeric isoflavones |
| 09/12/2002 | WO2002070479A1 N-4-piperidinyl compounds as ccr5 modulators |
| 09/12/2002 | WO2002070468A2 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity |
| 09/12/2002 | WO2002070438A2 Compositions for delivering bisphosphonates |
| 09/12/2002 | WO2002070023A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 09/12/2002 | WO2002070009A1 Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
| 09/12/2002 | WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | WO2002070007A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | WO2002069998A1 Regulating vegf expression by a protein of the tis11 family |
| 09/12/2002 | WO2002069988A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation |
| 09/12/2002 | WO2002069984A2 Use of hyaluronic acid uronides for the treatment of inflammatory processes |
| 09/12/2002 | WO2002069980A2 Pharmaceutically effective ginsenosides and their use |
| 09/12/2002 | WO2002069971A1 Pharmaceutical compositions and dietary supplements for treatment or improvement of arthitis |
| 09/12/2002 | WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | WO2002069905A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | WO2002069901A2 Cathepsin cysteine protease inhibitors |
| 09/12/2002 | WO2002069886A2 Modified proteins, designer toxins, and methods of making thereof |
| 09/12/2002 | WO2002069883A2 Cathecin derivatives as leukocyte elastase inhibitors for treating inflammatory disorders |
| 09/12/2002 | WO2002053175A3 Use of botulinum toxin for treatment of articular pathologies |
| 09/12/2002 | WO2002050030A3 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 09/12/2002 | WO2002028859A3 Condensed pyridoindole derivatives |
| 09/12/2002 | WO2002026717A3 Hydroxy acid integrin antagonists |
| 09/12/2002 | WO2002022680A3 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 09/12/2002 | WO2002014369A3 Human kininogen d5 domain polypeptides and their use |
| 09/12/2002 | WO2002012346A3 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 09/12/2002 | WO2002010351A3 Autologous connective tissues, methods for the production thereof and their use |
| 09/12/2002 | WO2002007748A3 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 09/12/2002 | WO2001096334A3 Heteroarylalkanoic acids as integrin receptor antagonists |
| 09/12/2002 | WO2001089520A3 Dehydroascorbic acid formulations and uses thereof |
| 09/12/2002 | WO2001017557A9 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| 09/12/2002 | WO2001012210A9 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 09/12/2002 | WO2001001996A9 Compositions and methods for treating or preventing osteoporosis |
| 09/12/2002 | US20020128510 Antiarthritic agents; rheumatic diseases; osteoarthritis; inhibition of the inducible nitric oxide synthase - induced after activation of vascular smooth muscle, macrophages, endothelial cells by enotoxin and cytokines |
| 09/12/2002 | US20020128483 Sulfonamide-containing indole compounds |
| 09/12/2002 | US20020128480 Pyrimidinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents |
| 09/12/2002 | US20020128471 Useful for treating cellular hyperproliferation |
| 09/12/2002 | US20020128444 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response |
| 09/12/2002 | US20020128436 Therapeutic composition for use in the treatment of autoimune and rheumatic diseases |
| 09/12/2002 | US20020128317 Administering diacerein or rhein to treat inflammatory and autoimmune conditions characterized by an increased IL-1 and or TNF alpha level |
| 09/12/2002 | US20020128308 Useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. |
| 09/12/2002 | US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction |
| 09/12/2002 | US20020128278 Inhibit some of the ill effects caused by diabetes or by aging; preventing premature aging, rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, atherosclerosis and spoilage of proteins in food |